Cyclo Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CYTH research report →
Companywww.cyclotherapeutics.com
Cyclo Therapeutics, Inc. , a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease.
- CEO
- N. Scott Fine
- IPO
- 2000
- Employees
- 8
- HQ
- Gainesville, FL, US
Price Chart
Valuation
- Market Cap
- $23.59M
- P/E
- -0.59
- P/S
- 21.92
- P/B
- 2.47
- EV/EBITDA
- -0.77
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 90.85%
- Op Margin
- -1862.69%
- Net Margin
- -1863.36%
- ROE
- -730.48%
- ROIC
- -346.28%
Growth & Income
- Revenue
- $1.08M · -21.76%
- Net Income
- $-20,057,302 · -31.27%
- EPS
- $-1.23 · 32.04%
- Op Income
- $-20,050,057
- FCF YoY
- -6.99%
Performance & Tape
- 52W High
- $1.62
- 52W Low
- $0.55
- 50D MA
- $0.80
- 200D MA
- $0.83
- Beta
- -0.57
- Avg Volume
- 1.76M
Get TickerSpark's AI analysis on CYTH
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 27, 25 | CONKLING WILLIAM | other | 27,654 |
| Feb 27, 25 | Wong Vivien | other | 25,140 |
| Feb 27, 25 | Cross Shawn | other | 28,597 |
| Feb 27, 25 | Toig Randall M. | other | 33,311 |
| Feb 27, 25 | STRATTAN CE RICK | other | 30,169 |
| Feb 27, 25 | Ostronic Francis Patrick | other | 70,329 |
| Feb 27, 25 | Sieger Markus | other | 58,138 |
| Feb 27, 25 | SHANAHAN WILLIAM S | other | 25,140 |
| Dec 23, 24 | Rafael Holdings, Inc. | other | 3,968,254 |
| Nov 15, 24 | CONKLING WILLIAM | other | 16,660 |
Our CYTH Coverage
We haven't published any research on CYTH yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CYTH Report →